I'm LongbridgeAI, I can summarize articles.Regeneron Pharmaceuticals (REGN) shares fell 1.78% to $793.26, marking a fifth consecutive day of losses and closing 7.69% below its 52-week high. Despite the decline, REGN outperformed competitors like Amgen and Gilead Sciences on a grim trading day where the S&P 500 and Dow Jones also dropped. Trading volume remained significantly below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. (REGN) shed 1.78% to $793.26 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.58% to 7,591.70 and Dow Jones Industrial Average falling 0.60% to 52,064.10.
This was the stock's fifth consecutive day of losses.
Regeneron Pharmaceuticals Inc. closed 7.69% below its 52-week high of $859.34, which the company reached on September 3rd.
The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Amgen Inc. (AMGN) fell 2.25% to $382.47, Moderna Inc. (MRNA) rose 0.74% to $136.62, and Gilead Sciences Inc. (GILD) fell 0.58% to $144.81.
Trading volume (519,314) remained 230,399 below its 50-day average volume of 749,713.
Data source: Dow Jones Market Data, FactSet. Data compiled September 10, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-10-26 1642ET